Encochleated amphotericin B (Matinas BioPharma)

两性霉素B (Matinas BioPharma)

Report date: 2026/03/12 20:00:16

Base Information

Drug NameEncochleated amphotericin B (Matinas BioPharma)
Drug Alias Nameoral lipid nanocrystal amphotericin B (Matinas BioPharma)MAT-2203
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of ActionCell membrane permeability enhancersErgosterol binders
TargetsErgosterol
Therapy Area/IndicationsVulvovaginitisLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma +[8
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUganda
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAquarius BioTechnologies Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMeningitis, CryptococcalCandidiasis, Chronic Mucocutaneous
Inactive IndicationsVulvovaginitisLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma +[6

Other Information

ATC CodeN/A
Related LinksN/A